公开(公告)号：US20240182603A1

公开(公告)日：2024-06-06

申请号：US18551000

申请日：2022-03-18

Applicant: Brandeis University

Inventor： Isaac J. Krauss ,  Leiming Tian

IPC: C08B37/00 ,  C07H21/00 ,  G01N33/68

CPC classification number: C08B37/006 ,  C07H21/00 ,  G01N33/6854 ,  G01N2400/02 ,  G01N2400/38

Abstract: Glycosylated peptides and oligonucleotides of the invention contain oligosaccharides that include three or more saccharide moieties, wherein two saccharide moieties at a non-reducing terminal end of the oligosaccharide are coupled together with a thio-ether bond, and one of the saccharide moieties at a reducing end of the oligosaccharide is coupled to a reactive moiety. Also disclosed are immunogenic conjugates that include a glycopeptide or oligonucleotide bound to an immunogenic carrier molecule, as well as pharmaceutical compositions containing the same.

公开(公告)号：US20240175073A1

公开(公告)日：2024-05-30

申请号：US18285031

申请日：2022-03-22

Applicant: SEKISUI MEDICAL CO., LTD.

Inventor： Tetsuo SEKINO ,  Akane OOMORI

IPC: C12Q1/6804 ,  G01N33/53 ,  G01N33/68

CPC classification number: C12Q1/6804 ,  G01N33/53 ,  G01N33/6854

Abstract: Provided is a method for measuring an anti-drug antibody that can be performed more simply and inexpensively than conventional methods. Provided is a double antigen bridging immunoassay using a capture nucleic acid and a tracer nucleic acid. By using the capture nucleic acid and the tracer nucleic acid in the double antigen bridging immunoassay, an anti-drug antibody can be measured simply and inexpensively. Furthermore, by using the tracer nucleic acid, it becomes possible to adopt a high sensitivity detection method utilizing a nucleic acid.

公开(公告)号：US11993646B2

公开(公告)日：2024-05-28

申请号：US16994837

申请日：2020-08-17

Applicant: KOTA BIOTHERAPEUTICS, LLC

Inventor： Roderick A. Hyde ,  Wayne R. Kindsvogel ,  Gary L. McKnight

IPC: C12N5/10 ,  A61K39/00 ,  C07K16/00 ,  C07K16/10 ,  C07K16/12 ,  C07K16/18 ,  C07K16/30 ,  C07K16/44 ,  C12N5/0781 ,  G01N33/68

CPC classification number: C07K16/18 ,  A61K39/00 ,  C07K16/00 ,  C07K16/1018 ,  C07K16/109 ,  C07K16/1271 ,  C07K16/3069 ,  C07K16/44 ,  C12N5/0635 ,  G01N33/6854 ,  A61K2039/505 ,  A61K2039/5156 ,  C07K2317/14 ,  C07K2317/33 ,  C07K2317/76 ,  C12N2510/00

Abstract: Compositions and methods are disclosed herein for producing one or more immunoglobulins in an isolated cytotoxic B lymphocyte cell line. An isolated cell line includes an isolated B lymphocyte cell line capable of expressing at least one exogenously incorporated membrane immunoglobulin capable of binding to a first antigen and at least one endogenous secreted immunoglobulin capable of binding to a second antigen, and further capable of expressing at least one exogenously incorporated recombinant B cell receptor that signals for expression of cytotoxic effector molecules.

公开(公告)号：US20240158485A1

公开(公告)日：2024-05-16

申请号：US18515723

申请日：2023-11-21

Applicant: Celros Biotech

Inventor： Yun Soo BAE ,  Eunjung AN ,  Jung-Yeon YOO ,  Hyunbo SHIM ,  Hye Eun LEE

IPC: C07K16/18 ,  A61P1/16 ,  A61P13/12 ,  G01N33/68

CPC classification number: C07K16/18 ,  A61P1/16 ,  A61P13/12 ,  G01N33/6854 ,  A61K2039/505

Abstract: The present disclosure relates to SH3YL1 monoclonal antibodies and compositions comprising the SH3YL1 monoclonal antibodies. The disclosure also relates to isolated nucleic acid molecules encoding the SH3YL1 antibodies, vectors comprising the nucleic acid molecules, and host cells comprising the vectors. Also disclosed are methods of modulating an immune response, methods of treating diabetic nephropathy, and methods of treating non-alcoholic steatosis hepatitis comprising administering the SH3YL1 antibodies. Also disclosed are methods of treating acute kidney injury and methods of treating inflammatory bowel disease comprising administering the SH3YL1 antibodies.

公开(公告)号：US20240150476A1

公开(公告)日：2024-05-09

申请号：US18393918

申请日：2023-12-22

Applicant: Chugai Seiyaku Kabushiki Kaisha

Inventor： Tomoyuki IGAWA ,  Hiroyuki ISHIKAWA ,  Naoka HIRONIWA

IPC: C07K16/28 ,  C07K16/30 ,  C40B40/10 ,  G01N33/68

CPC classification number: C07K16/2866 ,  C07K16/2809 ,  C07K16/303 ,  C40B40/10 ,  G01N33/6854 ,  C07K2317/22 ,  C07K2317/31 ,  C07K2317/569 ,  C07K2319/50

Abstract: The present invention relates to a polypeptide comprising an antigen binding domain and a carrying moiety having an inhibiting domain that inhibits the antigen binding activity of the antigen binding domain, and having a longer half-life than that of the antigen binding domain existing alone, methods for producing and screening for the polypeptide, a pharmaceutical composition comprising the polypeptide, methods for producing and screening for a single-domain antibody whose antigen binding activity is inhibited by associating with particular VL, VH or VHH, and a fusion polypeptide library including a single-domain antibody whose antigen binding activity is inhibited by associating with particular VL, VH or VHH.

公开(公告)号：US11976276B2

公开(公告)日：2024-05-07

申请号：US17520330

申请日：2021-11-05

Applicant: Memo Therapeutics AG

Inventor： Martin Held ,  Christoph Esslinger

IPC: C12N15/10 ,  C07K16/00 ,  C12Q1/6806 ,  C12Q1/686 ,  G01N33/50 ,  G01N33/68

CPC classification number: C12N15/1082 ,  C07K16/00 ,  C07K16/005 ,  C12Q1/6806 ,  C12Q1/686 ,  G01N33/5023 ,  G01N33/5047 ,  G01N33/6845 ,  G01N33/6854 ,  C12Q1/686 ,  C12Q2521/107 ,  C12Q2563/149 ,  C12Q2563/159 ,  C12Q1/6806 ,  C12Q2521/107 ,  C12Q2563/149 ,  C12Q2563/159

Abstract: The present invention is related to a method for recovering two or more genes, or gene products, or cDNAs, encoding for an immunoreceptor having two or more subunits, which two or more genes, or gene products, are comprised in a given source cell. The invention is further related to a method of creating a library of expressor cells, in which library each cell is capable of expressing two or more genes, or gene products, encoding for the subunits of the immunoreceptor. The invention is further related to a method of screening a library of expressor cells as created according to the above method, for one cell that expresses an immunoreceptor that has specificity for a given target molecule.

公开(公告)号：US20240125797A1

公开(公告)日：2024-04-18

申请号：US18262519

申请日：2022-01-26

Applicant: CZ Biohub SF, LL ,  The Board of Trustees of the Leland Stanford Junior University

Inventor： William J. Greenleaf ,  Amy F. Chen

IPC: G01N33/68

CPC classification number: G01N33/6854

Abstract: The invention provides compositions and methods for quantifying cellular molecules of interest, e.g., intracellular proteins, using oligonucleotide-target binding moiety conjugates.

公开(公告)号：US20240124593A1

公开(公告)日：2024-04-18

申请号：US18347626

申请日：2023-07-06

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Daniel J. Sexton ,  Christopher TenHoor ,  Malini Viswanathan

IPC: C07K16/28 ,  A61K39/395 ,  A61K48/00 ,  A61K49/00 ,  G01N33/68

CPC classification number: C07K16/283 ,  A61K39/3955 ,  A61K48/00 ,  A61K49/0002 ,  G01N33/6854 ,  A61K2039/505

Abstract: The disclosure relates to antibodies that bind FcRn and methods of using these antibodies.

公开(公告)号：US20240124519A1

公开(公告)日：2024-04-18

申请号：US18235015

申请日：2023-08-17

Applicant: Hoffmann-La Roche Inc.

Inventor： Roberto Falkenstein ,  Hubert Hertenberger ,  Petra Rueger ,  Tillman Schlothauer

IPC: C07K1/22 ,  B01D15/16 ,  B01D15/38 ,  B01J20/289 ,  B01J20/32 ,  B01J39/26 ,  C07K16/06 ,  C07K16/28 ,  G01N33/68

CPC classification number: C07K1/22 ,  B01D15/168 ,  B01D15/3809 ,  B01J20/289 ,  B01J20/3204 ,  B01J20/3206 ,  B01J20/3219 ,  B01J20/3274 ,  B01J39/26 ,  C07K16/065 ,  C07K16/2866 ,  G01N33/6854

Abstract: Herein is reported the use of an immobilized non-covalent complex of a neonatal Fc receptor (FcRn) and beta-2-microglobulin (b2m) as affinity chromotography ligand in general and, for example, for the determination of the in vivo half-live of an antibody by determining the ratio of the retention times of the antibody and a reference antibody.

公开(公告)号：US20240117047A1

公开(公告)日：2024-04-11

申请号：US18546081

申请日：2022-02-11

Applicant: The Regents of the University of California

Inventor： Thomas J. KIPPS ,  Charles E. PRUSSAK ,  George F. WIDHOPF, II

IPC: C07K16/28 ,  A61K47/68 ,  A61P35/00 ,  G01N33/68

CPC classification number: C07K16/2803 ,  A61K47/6849 ,  A61P35/00 ,  G01N33/6845 ,  G01N33/6854 ,  C07K2317/24 ,  C07K2317/622 ,  G01N2333/70567

Abstract: Provided herein are, inter alia, antibodies (e.g. humanized antibodies, monoclonal antibodies, antibody fragments (e.g., scFvs) and antibody compositions (e.g., chimeric antigen receptors, bispecific antibodies), which bind human tyrosine kinase-like orphan receptor 1 (ROR1) with high efficiency and specificity. The antibodies and antibody compositions provided herein include novel light and heavy chain domain CDRs and framework regions and are, inter alia, useful for diagnosing and treating cancer and other ROR1-related diseases.